Literature DB >> 29459643

Immunotherapy: Cancer immunotherapy and the value of cure.

Joseph C Del Paggio1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29459643     DOI： 10.1038/nrclinonc.2018.27

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

1.  Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

Authors:  Matthew D Hellmann; Mark G Kris; Charles M Rudin
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

2.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

Review 5.  Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry.

Authors:  Mark Slomiany; Priya Madhavan; Michael Kuehn; Sasha Richardson
Journal:  Am Health Drug Benefits       Date:  2017-07

6.  Hans Christian Andersen and the Value of New Cancer Treatments.

Authors:  Richard L Schilsky; Lowell E Schnipper
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

7.  Patient Versus Physician Valuation of Durable Survival Gains: Implications for Value Framework Assessments.

Authors:  Jason Shafrin; Taylor T Schwartz; Tony Okoro; John A Romley
Journal:  Value Health       Date:  2017-02       Impact factor: 5.725

8.  ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Authors:  N I Cherny; U Dafni; J Bogaerts; N J Latino; G Pentheroudakis; J-Y Douillard; J Tabernero; C Zielinski; M J Piccart; E G E de Vries
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

9.  Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.

Authors:  Omer Ben-Aharon; Racheli Magnezi; Moshe Leshno; Daniel A Goldstein
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

10.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Authors:  Courtney Davis; Huseyin Naci; Evrim Gurpinar; Elita Poplavska; Ashlyn Pinto; Ajay Aggarwal
Journal:  BMJ       Date:  2017-10-04
View more
  28 in total

1.  Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.

Authors:  Min-Hee Oh; Im-Hong Sun; Liang Zhao; Robert D Leone; Im-Meng Sun; Wei Xu; Samuel L Collins; Ada J Tam; Richard L Blosser; Chirag H Patel; Judson M Englert; Matthew L Arwood; Jiayu Wen; Yee Chan-Li; Lukáš Tenora; Pavel Majer; Rana Rais; Barbara S Slusher; Maureen R Horton; Jonathan D Powell
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.

Authors:  Lingli Huang; Xin Liu; Li Li; Lei Wang; Nan Wu; Zhixian Liu
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

3.  SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer.

Authors:  Siyuan Weng; Zaoqu Liu; Xiaofeng Ren; Hui Xu; Xiaoyong Ge; Yuqing Ren; Yuyuan Zhang; Qin Dang; Long Liu; Chunguang Guo; Richard Beatson; Jinhai Deng; Xinwei Han
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

4.  Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles.

Authors:  Tian Tian; Ruyu Liang; Gulsah Erel-Akbaba; Lorenzo Saad; Pierre J Obeid; Jun Gao; E Antonio Chiocca; Ralph Weissleder; Bakhos A Tannous
Journal:  ACS Nano       Date:  2022-01-31       Impact factor: 18.027

5.  TP53 Mutations Promote Immunogenic Activity in Breast Cancer.

Authors:  Zhixian Liu; Zehang Jiang; Yingsheng Gao; Lirui Wang; Cai Chen; Xiaosheng Wang
Journal:  J Oncol       Date:  2019-06-02       Impact factor: 4.375

6.  ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.

Authors:  Houshi Xu; Anke Zhang; Xiaying Han; Yanning Li; Zeyu Zhang; Liying Song; Wei Wang; Meiqing Lou
Journal:  Cancer Immunol Immunother       Date:  2021-07-27       Impact factor: 6.968

Review 7.  Role and Therapeutic Potential of Melatonin in the Central Nervous System and Cancers.

Authors:  Sangiliyandi Gurunathan; Min-Hee Kang; Jin-Hoi Kim
Journal:  Cancers (Basel)       Date:  2020-06-13       Impact factor: 6.639

8.  Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Authors:  Steven F Gameiro; Farhad Ghasemi; John W Barrett; James Koropatnick; Anthony C Nichols; Joe S Mymryk; Saman Maleki Vareki
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

Review 9.  Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.

Authors:  Shan Gao; Dongjuan Yang; Yan Fang; Xiaojie Lin; Xuechao Jin; Qi Wang; Xiyan Wang; Liyuan Ke; Kai Shi
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

10.  A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.

Authors:  Song Li; Jing Gao; Qian Xu; Xue Zhang; Miao Huang; Xin Dai; Kai Huang; Lian Liu
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.